This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
GEHC Stock Surges as SIGNA Sprint MRI Redefines 1.5T Imaging Tech
by Zacks Equity Research
GE HealthCare unveils SIGNA Sprint MRI, a high-performance 1.5T system designed to boost diagnostic accuracy, accelerate imaging, and advance cardiac and cancer care.
PACB Stock May Rise Following the Deal With Chulalongkorn University
by Zacks Equity Research
PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.
TMDX Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down
by Zacks Equity Research
Increased organ utilization in liver and continued OCS adoption across both liver and heart boosted TransMedics' first-quarter 2025 performance.
AMN Stock Gains Following Q1 Earnings & Revenue Beat, Margins Down
by Zacks Equity Research
AMN Healthcare's dismal results in all its segments led to a soft overall first-quarter 2025 performance.
PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates
by Zacks Equity Research
Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments.
CVS vs. DHR: Which Stock Is the Better Value Option?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline
by Zacks Equity Research
SOLV's first-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off
by Zacks Equity Research
McKesson's fourth-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
QuidelOrtho Stock Gains Following Q1 Earnings Beat, Margins Expand
by Zacks Equity Research
Despite solid performances by the Labs and Immunohematology units and EMEA and Other regions, QDEL reports soft overall top-line results in first-quarter 2025.
INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales.
XRAY Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down
by Zacks Equity Research
DENTSPLY SIRONA's customer-centric innovation and operational efficiency drive its first-quarter 2025 performance despite global macroeconomic challenges.
Is First Trust Large Cap Value AlphaDEX ETF (FTA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTA
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised
by Zacks Equity Research
COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.
AVNS Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down
by Zacks Equity Research
Strength in Avanos' SNS segment drives its first-quarter 2025 performance despite global macroeconomic challenges.
FMS Stock Up as Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Fresenius Medical's first-quarter results showcase a strong segmental performance, along with reiterating its 2025 outlook for revenue growth.
CLOV Stock Rises as Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Clover Health's first-quarter 2025 results continue to benefit from the strength of its strong member retention. A decline in operating loss bodes well.
MASI Stock Slips Despite Q1 Earnings and Revenue Beat, Margins Expand
by Zacks Equity Research
Masimo's first-quarter 2025 results continue to benefit from the strength in its Healthcare businesses despite tariff-related uncertainties.
HIMS Stock Dips Pre-Market Despite Q1 Earnings Beat, Gross Margin Down
by Zacks Equity Research
Hims & Hers' first-quarter 2025 performance reflects continued strength in its online revenue channel on the back of solid product demand and an increasing subscriber base.
INSP Stock Gains Following Q1 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Inspire Medical's first-quarter 2025 performance reflects increased market penetration in existing centers and expansion into new territories and centers, along with strong domestic results.
What Makes CVS Health (CVS) a New Buy Stock
by Zacks Equity Research
CVS Health (CVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think CVS Health (CVS) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for CVS Health (CVS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Is Most-Watched Stock CVS Health Corporation (CVS) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should First Trust Large Cap Core AlphaDEX ETF (FEX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FEX
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG